Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
Status:
Terminated
Trial end date:
2021-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test if an experimental drug called Durvalumab (Medi4736)
given by intravenous (IV) infusion is effective in treating carcinoma in situ (CIS) of the
bladder that no longer responds to Bacillus Calmette-Guérin (BCG) and to collect information
on the safety of these drugs and whether they cause any side effects.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute